Top Page
Burcon Nutrascience
(OTC:BU)
Burcon Nutrascience (BU) vs. S&P 500 (SPY)
Burcon Nutrascience Business Overview & Revenue Model
Burcon Nutrascience Financial Statement Overview
| Breakdown | |||||
| TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 420.98K | 184.36K | 363.91K | 171.47K | 258.65K | 31.13K | Gross Profit |
| -167.09K | 184.36K | 363.91K | 171.47K | -527.31K | -815.00K | EBIT |
| -7.46M | -7.02M | -7.53M | -7.40M | -4.60M | -3.72M | EBITDA |
| -6.66M | -6.74M | -18.90M | -9.92M | 2.87M | -3.69M | Net Income Common Stockholders |
| -7.40M | -7.45M | -25.36M | -10.26M | -617.49K | -4.63M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 675.38K | 4.20M | 1.46M | 7.00M | 13.97M | 15.03M | Total Assets |
| 8.74M | 12.91M | 9.90M | 29.35M | 37.72M | 31.27M | Total Debt |
| 5.32M | 6.67M | 5.17M | 73.14K | 33.70K | 6.73M | Net Debt |
| 4.65M | 2.47M | 3.71M | -6.93M | -13.94M | -8.30M | Total Liabilities |
| 5.95M | 7.76M | 5.76M | 1.10M | 1.45M | 8.32M | Stockholders Equity |
| 2.79M | 5.15M | 4.14M | 28.25M | 36.27M | 22.95M |
| Cash Flow | Free Cash Flow | ||||
| -6.61M | -5.90M | -6.38M | -7.18M | -5.91M | -4.31M | Operating Cash Flow |
| -6.33M | -5.78M | -6.02M | -5.91M | -3.03M | -2.74M | Investing Cash Flow |
| -249.40K | -39.49K | -4.43M | -1.23M | -2.72M | -14.57M | Financing Cash Flow |
| 5.13M | 8.56M | 4.90M | 174.08K | 4.70M | 31.85M |
Burcon Nutrascience Technical Analysis
Burcon Nutrascience Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | C$3.44B | 27.99 | 6.86% | 4.44% | 3.35% | 28.80% | |
63 Neutral | $20.41B | 13.98 | -16.01% | 3.26% | 1.30% | 5.01% | |
50 Neutral | C$21.57M | ― | -574.03% | ― | 83.65% | 3.91% | |
50 Neutral | C$1.35B | ― | -0.38% | ― | 18.07% | 98.61% | |
45 Neutral | ― | -10.69% | ― | ― | ― | ||
43 Neutral | C$16.29M | ― | 11.42% | ― | -9.16% | 53.81% |
Burcon Nutrascience Earnings Call Summary
Burcon Nutrascience Corporate Events
Burcon NutraScience Corporation has successfully installed and commissioned its proprietary protein processing equipment at its Galesburg, Illinois facility, marking a significant step in its operational expansion. This development positions Burcon to scale up production, optimize operations, and enhance commercial partnerships, reinforcing its role as a key player in the expanding plant-based protein market.
Burcon NutraScience Corporation announced that its alliance partner, RE ProMan, LLC, has completed the acquisition of a protein production facility in Galesburg, Illinois. This acquisition allows Burcon to integrate its technologies into the facility, which is strategically located for efficient production and distribution. The facility’s acquisition marks a significant milestone for Burcon, providing the company with full operational control of a commercial facility for the first time. This development enables Burcon to deliver high-quality, sustainable plant-based protein solutions, meeting growing consumer demand and accelerating market adoption of its innovative protein ingredients.
Burcon NutraScience Corporation has successfully completed a rights offering, raising approximately $9.43 million through the issuance of over 110 million common shares. The proceeds are intended to support the commercialization and production scaling of Burcon’s protein products, alongside funding a manufacturing agreement with RE ProMan, LLC. The rights offering was well-supported by strategic investors and insiders, solidifying Burcon’s capital position to pursue growth opportunities.
Burcon NutraScience Corporation reported significant advancements in its operations during the fiscal third quarter of 2025, notably gaining full operational control of a protein production facility. This strategic move, in partnership with Re ProMan LLC, is pivotal in Burcon’s commercialization efforts and reflects confidence in their market potential. The company also launched several new protein products, entered collaborations to explore new applications, and secured funding through a rights offering, positioning itself for accelerated growth and innovation in plant-based proteins.
Burcon NutraScience Corporation has successfully completed its $9.43 million rights offering, surpassing the $7 million needed to execute its production strategy and aim for positive cash flow by 2026. This financial milestone is expected to strengthen Burcon’s market position as a leader in protein innovation, reflecting strong shareholder confidence in its strategic direction.
Burcon NutraScience is set to host a virtual investor presentation on February 18, 2025, to discuss recent milestones and future plans. The company will outline its strategy to bring its entire protein portfolio to market, supported by an acquisition by Re ProMan LLC. This move is expected to enhance Burcon’s market operations and drive revenue growth, reinforcing its position in the plant-based industry.
Burcon NutraScience has entered into an agreement with RE ProMan, LLC to establish a protein production facility in North America. This strategic partnership aims to enhance Burcon’s market presence by granting them exclusive access to manufacturing capacity for their plant protein products, expecting significant revenue growth and profitability by 2026.
Burcon NutraScience’s alliance partner, RE ProMan, LLC, has signed an agreement to acquire a protein production facility in North America. This strategic move allows Burcon to gain control over commercial production, facilitating the market entry of their protein products by the first half of 2025. The acquisition reflects confidence in Burcon’s proprietary technologies and aligns with their capital-light strategy, potentially enhancing their market position and offering benefits to stakeholders through expanded production capabilities.